A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study

Randomised, placebo-controlled feasibility study in adults (25–80 years) with treatment-resistant depression testing a single 25 mg oral dose of psilocybin with psychological support.

Primary aim is feasibility; outcomes include safety, tolerability, and depressive symptom change following a single dosing session with preparatory and integration therapy.